Friday, March 27, 2026 For Patients CME Credits Newsletters
Subscribe

Predictors of Saccadic Reaction Time in Zambian Children: Birth Spacing, Nutrition, and Diarrhea Impact

Key Takeaway
Consider nutritional diversity and health status when assessing child development in LMICs.

This randomized controlled trial examined predictors of saccadic reaction time (SRT) among 299 children in Lusaka, Zambia, as part of a larger 2x2 cluster-randomized trial. The study aimed to identify factors influencing SRT, a measure of visual processing speed, and its correlation with early childhood development (ECD) metrics such as Global Scales of Early Development (GSED) development-for-age Z-score (DAZ), height-for-age Z-score (HAZ), and head circumference-for-age Z-score (HCZ). SRT was measured at approximately 31 months using a Tobii Pro Fusion tracker. Significant predictors of SRT in the multivariable model included being the only child under five in the household (β: -10.02, 95% CI: -19.71, -0.33, p=0.04), baseline length-for-age Z-score (LAZ) (β: -3.17, 95% CI: -6.31, -0.04, p=0.047), consuming four or more food groups in the past day (β: -10.42, 95% CI: -19.98, -0.86, p=0.03), and having diarrhea in the past two weeks (β: 12.38, 95% CI: 0.71, 24.06, p=0.04). SRT was negatively correlated with HAZ (r=-0.176, p<0.01) and HCZ (r=-0.132, p<0.05), but not with GSED DAZ. These findings suggest that birth spacing, nutritional diversity, and recent diarrheal episodes are significant factors affecting SRT and potentially ECD in this population. No safety or adverse events were reported. The study underscores the importance of addressing nutritional and health factors to improve developmental outcomes in children from low- and middle-income countries.

AI Accuracy Review: 9/10 · Auto-published
View Original Abstract ↓
Saccadic reaction time (SRT), an assessment of visual processing speed, may afford an accurate and unbiased measure of early childhood development (ECD). Few studies have examined SRT in low- and middle-income countries (LMICs), including its drivers. We sought to identify predictors of SRT as well as to assess the correlation between SRT and concurrent measures of ECD [Global Scales of Early Development (GSED) development-for-age Z-score (DAZ), height-for-age Z-score (HAZ), and head circumference-for-age Z-score (HCZ)], among young children in Lusaka, Zambia. We conducted a sub-study among 299 Lusakan children participating in a 2x2 cluster-randomized trial. SRT was assessed at ~31 months using a screen-based setup with a Tobii Pro Fusion tracker. Associations with household, caregiver, and child characteristics were assessed using univariable regression models; predictors significant at the p < 0.20 level were retained in a multivariable model. Pearson correlation coefficients were calculated to assess associations between SRT and other concurrent measures of ECD. In the multivariable model, characteristics found to be significant predictors of SRT included: being the only child <5 in the household at baseline (β: -10.02, 95% CI: -19.71, -0.33, p = 0.04), length-for-age Z-score (LAZ) at baseline (β: -3.17, 95% CI: -6.31, -0.04, p = 0.047), consuming ≥4 food groups in the past day (β: -10.42, 95% CI: -19.98, -0.86, p = 0.03), and having diarrhea in the past 2 weeks (β: 12.38, 95% CI: 0.71, 24.06, p = 0.04). SRT was significantly negatively correlated with HAZ (-0.176, p < 0.01) and HCZ (-0.132, p < 0.05), but not GSED DAZ. Overall, we identified several significant predictors of SRT among young children in Lusaka, Zambia, including birth spacing, baseline LAZ, dietary diversity, and diarrheal disease. Further research is needed, including in different age groups and geographic locations, to better understand the drivers of slow SRT, and poor ECD generally, in LMICs.
CT.gov · Phase 3 Trial Evaluates Safety and Immunogenicity of CHIKV VLP Vaccine in Childr… CT.gov · Phase 2 Study: L-SABR Plus Standard Therapy in Metastatic NSCLC Patients CT.gov · Ivonescimab Phase II Study Targets 55% DCR in Relapsed Pleural Mesothelioma CT.gov · Phase 2 Study Evaluates Frexalimab, Brivekimig, Rilzabrutinib in FSGS and MCD CT.gov · Phase 2 Study: ManNAc for FSGS Shows Promise in Reducing Proteinuria CT.gov · Phase 3 Trial: Anifrolumab Shows Promise in SLE with BICLA Response as Primary O…